SCHEMBL680135

SCHEMBL680135

CCOC(=O)c1cc2c(cnn2C2CCCCO2)cc1Oc1ccc([N+](=O)[O-])cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
MITF O75030 2/20 0.37
RAB9A P51151 1/20 0.37
AR P10275 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 4/20 0.37
ALDH1A1 P00352 5/20 0.36
LMNA P02545 1/20 0.36
EGFR P00533 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
ELANE P08246 1/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
CASP3 P42574 1/20 0.34
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679190 0.89 RXRA (0.43) RXRARXRBRXRGRAB9ASMN1; SMN2
SCHEMBL680051 0.86 RXRA (0.42) RXRARXRBRXRGRAB9ASMN1; SMN2
SCHEMBL679563 0.84 ALDH1A1 (0.38) RXRARXRBRXRGALDH1A1MAPK14
SCHEMBL679462 0.83 RXRA (0.39) RXRARXRBRXRGRAB9ASMN1; SMN2
SCHEMBL678989 0.83 MAPT (0.44) MITFARSMN1; SMN2MAPTALDH1A1
SCHEMBL680373 0.83 EGFR (0.40) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL679898 0.82 RXRA (0.38) RXRARXRBRXRGMAPTALDH1A1
SCHEMBL680965 0.82 RXRA (0.40) RXRARXRBRXRGMAPTALDH1A1
SCHEMBL680011 0.81 RXRA (0.37) RXRARXRBRXRGRAB9ASMN1; SMN2
SCHEMBL679314 0.80 RXRA (0.38) RXRARXRBRXRGSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.